Brief: Brainstorm Cell Therapeutics Reaches Alignment With FDA On CMC Aspects Of Phase 3b NurOwn® Clinical Trial
26/06/2024 13:15
June 26 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS REACHES ALIGNMENT WITH FDA ON
CMC
ASPECTS OF PHASE 3B NUROWN® CLINICAL TRIAL
* BRAINSTORM CELL THERAPEUTICS INC - ALIGNMENT WITH FDA ON
NUR OWN
CMC ASPECTS
Source text for Eikon: ID:nPn1hqhN9a
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview